Sequential Release of Pooled siRNAs and Paclitaxel by Aptamer-Functionalized Shell–Core Nanoparticles to Overcome Paclitaxel Resistance of Prostate Cancer

Qianqian Guo,Yang Dong,Yanhua Zhang,Hao Fu,Chuanrong Chen,Liting Wang,Xupeng Yang,Ming Shen,Jian Yu,Meiwan Chen,Jiali Zhang,Yourong Duan

DOI: https://doi.org/10.1021/acsami.1c00852

2021-03-19

Abstract:Paclitaxel (PTX) is a first-line chemotherapeutic agent to treat prostate cancer (PCa), but a large number of patients acquired drug resistance after short-term treatment. To develop combinational therapeutics to overcome PTX-resistant PCa, we established PTX-resistant LNCaP (LNCaP/PTX) cells and found that the LNCaP/PTX cells exhibited epithelial–mesenchymal transition (EMT) and enhanced metastasis during the selection process. We revealed that β-tubulin III, androgen receptor, and CXCR4 expressions were significantly increased in LNCaP/PTX cells and directly contributed to PTX resistance and EMT. Therefore, we developed prostate-specific membrane antigen aptamer (Apt)-functionalized shell–core nanoparticles (PTX/siRNAs NPs-Apt); the hydrophobic DSPE encapsulating PTX formed the dense inner core and the hydrophilic Apt-PEG_2K with calcium phosphate (CaP) absorbing siRNAs formed the outer shell to sequentially release siRNAs and PTX, where CaP could trigger lysosomal escape to ensure that pooled siRNAs efficiently released into the cytoplasm to reverse EMT and resensitize PTX, while the PTX located in the core was subsequently released to exert the killing effect of chemotherapy to achieve the best synergistic effect. PTX/siRNAs NPs-Apt showed an enhanced tumor-targeting ability and achieved superior efficacy in the subcutaneous and orthotopic PCa tumor model with minimal side effects.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c00852?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c00852</a>.Expression level of P-gP and β-tubulin III in LNCaP and LNCaP/PTX cells detected by western blot; LNCaP/PTX cells was co-cultured with PBS, DHT, SDF-1α, or DHT + SDF-1α for 72 h for transwell assay and clone formation assay; infrared characterization spectra of DSPE-PEG_2K-COOH and DSPE-PEG_2K-Apt; cell viability of mouse fibroblast L929 cells and LNCaP/PTX cells with the treatment of various concentrations of blank Apt-NPs for 24, 48 ,and 72 h; investigation of shell–core nanoparticles in the LNCaP/PTX cell cycle-blocking ability by flow cytometry and apoptosis of LNCaP/PTX cells and different components after 72 h incubation; wound healing assay and invasion assay examined the cell migration ability after 72 h of incubation; pharmacokinetics of siRNAs and PTX; tumor inhibition rate in different groups; tumor sections were stained with Ki-67 and Bcl-2; body weight curves of tumor-bearing mice under different treatments; indices of hepatic functions after the final injection of different drug formulations in nude mice; histopathology of major organs after the final injection of different drug formulations in nude mice; small animal magnetic resonance imaging system and small animal ultrasound imaging system monitor mouse orthotopic prostate tumor size and tumor inhibition rate in different groups; tumor and lymph node metastases in different groups of mice three days after the last dose and normal intestinal tissue and mesenteric lymph node metastases; prostate and seminal vesicle location in Balb/c nude male mice (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c00852/suppl_file/am1c00852_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,nanoscience & nanotechnology